Business

LEVBIO: 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution

LEVBIO: 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution

Level Bio AbApril 23, 20264
LEVBIO: 15% sales growth and CyberGene divestment signal a strategic focus on diagnostics distribution

About this update from Level Bio Ab

Net sales rose 15% year-over-year with a 52% gross margin, while the divestment of CyberGene marks a strategic shift toward diagnostics distribution. The sale strengthens the balance sheet but will lower future revenue and margin base.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Level Bio Ab